Press Releases on March 22, 2024 - EIN Presswire - Press Release Distribution Service

Published on March 22, 2024 - 14:14 GMT

Human medicines European public assessment report (EPAR): Omlyclo, omalizumab, Status: Opinion

On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Omlyclo, intended for the treatment of severe persistent allergic …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on March 22, 2024 - 14:14 GMT

Human medicines European public assessment report (EPAR): Awiqli, Insulin icodec, Status: Opinion

On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Awiqli, intended for the treatment of diabetes mellitus. The applicant …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on March 22, 2024 - 14:14 GMT

Human medicines European public assessment report (EPAR): Dimethyl fumarate Accord, dimethyl fumarate, Status: Opinion

On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Dimethyl fumarate Accord, intended for the treatment of multiple …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on March 22, 2024 - 14:14 GMT

Summary of opinion: Nilemdo, 21/03/2024 Positive

On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Nilemdo. The marketing authorisation holder for this …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on March 22, 2024 - 14:14 GMT

Human medicines European public assessment report (EPAR): Agilus, Dantrolene sodium,hemiheptahydrate, Status: Opinion

On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Agilus1, intended for the treatment of malignant hyperthermia in …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on March 22, 2024 - 14:14 GMT

Human medicines European public assessment report (EPAR): Jubbonti, denosumab, Status: Opinion

On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Jubbonti, intended for the treatment of osteoporosis in women who have …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on March 22, 2024 - 14:14 GMT

Human medicines European public assessment report (EPAR): Dimethyl fumarate Neuraxpharm, dimethyl fumarate, Status: Opinion

On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Dimethyl fumarate Neuraxpharm, intended for the treatment of multiple …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on March 22, 2024 - 14:14 GMT

First oral monotherapy for patients with paroxysmal nocturnal haemoglobinuria

EMA has recommended granting a marketing authorisation in the European Union (EU) for Fabhalta (iptacopan), an oral treatment for adults with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia. PNH is a rare genetic disorder that causes …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on March 22, 2024 - 14:13 GMT

Withdrawn application: Orencia, 19/02/2024

Based on the review of the information and the company’s response to the Agency’s questions, at the time of the withdrawal, the Agency had some concerns, and its provisional opinion was that Orencia could not have been authorised for the prevention of …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on March 22, 2024 - 14:14 GMT

Human medicines European public assessment report (EPAR): Dimethyl fumarate Mylan, dimethyl fumarate, Status: Opinion

On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Dimethyl fumarate Mylan, intended for the treatment of multiple …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on March 22, 2024 - 14:14 GMT

Human medicines European public assessment report (EPAR): Neoatricon, Dopamine hydrochloride, Status: Opinion

On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a paediatric use marketing authorisation (PUMA) for the medicinal product Neoatricon, intended for treatment of hypotension …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on March 22, 2024 - 14:13 GMT

Withdrawn application: Ongentys, 12/03/2024

Based on the review of the information and the company’s response to the Agency’s questions, at the time of the withdrawal, the Agency had some concerns and its provisional opinion was that Ongentys could not have been authorised for the treatment of signs …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on March 22, 2024 - 14:13 GMT

Referral: Micrazym and associated names, porcine pancreas enzymes Article 29(4) referrals CHMP opinion, 21/03/2024

Avva Pharmaceuticals Ltd. submitted a marketing authorisation application for Micrazym to the Netherlands for a decentralised procedure. This is a procedure where one Member State (the ‘reference Member State’, in this instance the Netherlands) assesses a …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on March 22, 2024 - 14:13 GMT

Human medicines European public assessment report (EPAR): Fabhalta, Iptacopan, Status: Opinion

On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Fabhalta1, intended for the treatment of paroxysmal nocturnal …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on March 22, 2024 - 14:13 GMT

Referral: Veterinary medicinal products containing N-methyl pyrrolidone as an excipient Article 82 European Commission final ...

Overview New measures to reduce risks from exposure to the excipient N-methyl pyrrolidone in veterinary medicines On 8 December 2022, EMA’s veterinary medicines committee, CVMP, recommended new measures to reduce the risks from exposure to N-methyl …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on March 22, 2024 - 14:13 GMT

- Utah's Employment Summary: February 2024

SALT LAKE CITY (March 22, 2024) — Utah’s nonfarm payroll employment for February 2024 increased an estimated 1.9% across the past 12 months, with the state’s economy adding a cumulative 32,600 jobs since February 2023. Utah’s current job count stands at 1, …

Distribution channels:

Published on March 22, 2024 - 14:13 GMT

Match Day 2024: Welcome Class of 2024

Years of hard work and dreams were folded into envelopes, decorative boxes and other means of message delivery. On March 15th, medical students discovered where their career journey would take them for residency. The University of North Carolina at Chapel …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on March 22, 2024 - 14:13 GMT

Wellness Tourism Market Size & Share to Surpass $1,592.6 Billion by 2030, Exhibiting a CAGR of 7.2% From 2021-2030

The lodging segment held the highest share, accounting for 20.6% of the global wellness tourism industry in 2020. WILMINGTON, NEW CASTLE, DELAWARE 19801 USA, UNITED STATES, March 22, 2024 /⁨EINPresswire.com⁩/ -- According to a new report published by …

Distribution channels: Agriculture, Farming & Forestry Industry, Travel & Tourism Industry ...

Published on March 22, 2024 - 14:13 GMT

New excitation method of stimulated Raman scattering achieves natural-linewidth-limit spectral lines

USA, March 22, 2024 /⁨EINPresswire.com⁩/ -- Current mainstream hyperspectral stimulated Raman scattering (SRS) techniques usually have to make a compromise between the spectral resolution and the detection sensitivity. Now, researchers at Peking University …

Distribution channels: IT Industry, Science ...

Published on March 22, 2024 - 14:11 GMT

Shapiro Administration Invests in Pittsburgh-Based Big Jet LLC’s Growth in Pennsylvania

Big Jet LLC, a minority-owned company, will use the Pennsylvania Minority Business Development Authority loan for operating expenses and will create two new jobs. Governor Josh Shapiro is committed to making transformational investments in our small, …

Distribution channels: